SALIL KATHPALIA: Open Payments
NPI 1295875714 · NEWBURGH, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$882 in 40 payments from 10 companies in 2025. Trend: 2023 $603 · 2024 $1,189 · 2025 $882
Food & beverage: $882
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $238 |
| Axsome Therapeutics, Inc. | 5 | $200 |
| Neurocrine BioSciences, Inc. | 4 | $96 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $89 |
| ABBVIE INC. | 4 | $81 |
| Alkermes, Inc. | 3 | $61 |
| E.R. Squibb & Sons, L.L.C. | 3 | $61 |
| Lundbeck LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
Products named: AUSTEDO XR, Auvelity, INGREZZA, CAPLYTA, VRAYLAR, ARISTADA, COBENFY, REXULTI.
Industry payments across NY — which companies pay providers there.
